Acquired demyelinating polyradiculoneuropathies;Neuropathies demyelinisantes acquises

Revue du Praticien

Volumn 50, Issue 7, 2000, Pages 724-730

  Hahn, Angelika F ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; EPITOPE; GANGLIOSIDE; IMMUNOGLOBULIN G; MYELIN; PREDNISONE;

CAMPYLOBACTER JEJUNI; CLINICAL TRIAL; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; PLASMAPHERESIS; REVIEW; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CHRONIC DISEASE; DEMYELINATING DISEASE; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; POLYNEUROPATHY;

ADRENAL CORTEX HORMONES; ANTIBODY FORMATION; CHRONIC DISEASE; DEMYELINATING DISEASES; GUILLAIN-BARRE SYNDROME; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFLAMMATION; PATIENT CARE PLANNING; POLYNEUROPATHIES;

EID: 0034175525     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Hughes RA, Rees JH. Clinical and epidemiological features of Guillain-Barré syndrome. J Infect Dis 1997 ; 176 : S92-S98.
2. Asbury AK, Cornblath DR.Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990 ; 27 : S21-S24.
3. Ropper AH.The Guillain-Barré syndrome. N Engl J Med 1992 ; 326 : 1130-6.
4. Ho TW, Willison HJ, Nachamkin I et al. Anti-GDIa antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999 ; 45 : 168-73.
5. Visser LH, Van Der Meche FG, Meulstee J et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996 ; 47 : 668-73.
6. Jacobs BC, Rothbarth PH, Van Der Meche FG et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998 ; 51 : 1110-5.
7. Sheikh KA, Nachamkin I, Ho TW et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility. Neurology 1998 ; 51 : 371-8.
8. Giovannoni G, Hartung HP.The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 1996 ; 9 : 165-77.
9. Hadden RD, Cornblath DR, Hughes RA et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998 ; 44 : 780-8.
10. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997 ; 349 : 225-30.
11. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993 ; 341 : 586-90.
12. Hughes RAC, Van Der Meché FGA. Systematic review of corticosteroid treatment for Guillain-Barré syndrome. Neurology 1999; 52:A127-A128.
13. The Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985 ; 35 : 1096-104.
14. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up.Ann Neurol 1992 ; 32 : 94-7.
15. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997 ; 41 : 298-306.
16. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975 ; 50 : 621-37.
17. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993 ; 43 : 2202-9.
18. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995 ; 118 : 359-68.
19. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies,and initial clinical course, with comparison to adults. Muscle Nerve 1997 ; 20 : 1008-15.
20. Oh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neu ropathy. J Neurol Neurosurg Psychiat 1992 ; 55 : 677-80.
21. Thomas PK, Claus D, Jaspert A et al. Focal upper limb demyelinating neuropathy. Brain 1996 ; 119 : 765-74.
22. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991 ; 41 : 617-8.
23. Notermans NC, Wokke JHJ, Lokhorst HM, Franssen H, Van Der Graaf Y, Jennekens GFI. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: a prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994 ; 117 : 1385-93.
24. Chassande B, Leger JM, Ben Younes-Chennoufi A et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998 ; 21 : 55-62.
25. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in South-East England. J Neurol Neurosurg Psychiatry 1999 ; 66 : 677-80.
26. Mohamed A, Pollard J, Walsh JC. Prevalence of CIDP in NSW. J Clin Neurosci 1997; 4: 403.
27. Bouchard C, Lacroix C, PlanteV et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999 ; 52 : 498-503.
28. Dyck PJ, O'Brien PC, Oviatt KF et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982 ; 11 : 136-41.
29. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987 ; 110 : 1617-30.
30. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria.Arch Neuroi 1989 ; 46 : 878-84.
31. Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996 ; 119 : 1055-66.
32. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996 ; 119 : 1067-77.
33. Parry GJ, Sumner AJ. Multifocal motor neuropathy.Neural Clin 1992 ; 10 : 671-84.
34. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998 ; 51 : S22-S24.
35. Bouche P, Moulonguet A, Ben Younes-Chennoufi A et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995 ; 59 : 38-44.
36. Van Es HW, Van Den Berg LH, Fradnssen H et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 1997 ; 48 : 1218-24.
37. Oh SJ, Claussen GC, Odabasi Z, Palmer CP. Multifocal demyelinating motor neuropathy: pathologic evidence of «inflammatory demyelinating polyradiculoneuropathy» Neurology 1995 ; 45 : 1828-32.
38. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GMI ganglioside antibodies in most patients detected using covalent linkage of GMI to ELISA plates. Neurology 1997 ; 49 : 1289-92.
39. Bech E, Andersen H, Omtoft TF, Jakobsen J. Association of IgM type anti-GMI antibodies and muscle strength in chronic acquired demyelinating polyneuropathy. Ann Neurol 1998 ; 43 : 72-8.
40. Donaghy M, Mills KR, Boniface SJ et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994 ; 57 : 778-83.
41. Azulay JP, Rihet P, Pouget J et al. Long term follow-up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 1997 ; 62 : 391-4.
42. Van Den Berg LH, Franssen H, Wokke JHJ. The long term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998 ; 121 : 421-8.